BiologicalDrug

Obiltoxaximab clinical trials

Also written ETI-204.

studies test it: 7
open now: 1
in phase 3: 0
first study started: 2005

How each study uses obiltoxaximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the obiltoxaximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: 18 Mar 2016 · ANTHIM · BLA 125509 (FDA, Drugs@FDA)
European Union: 18 Nov 2020 · Nyxthracis (previously Obiltoxaximab SFL) · EMEA/H/C/005169 (EMA; now withdrawn)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Obiltoxaximab: 2
ETI-204, "Anthim": 2

Brand

Anthim: 1

Development codes

ETI-204: 4

Studies by the year they started

7 studies that test it; most in 2013 (3)

Studies that test obiltoxaximab, by start year
Year	Studies
2005	1
2009	1
2011	1
2013	3
2023	1

By phase

A phase 1/2 study counts in both.

Phase 1: 6
Phase 4: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Anthrax: 5

Who runs them

Industry 0 · Other 7

Elusys Therapeutics (6) · National Institute of Allergy and Infectious Diseases (NIAID) (1)

Often tested with

Tested in the same studies.

Ciprofloxacin (1)

Studies

Open first, then newest update. How each study uses obiltoxaximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Given beside what is tested · 1 — obiltoxaximab is usual care or a partner of the new treatment

Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult VolunteersCompletedPhase 1Elusys TherapeuticsNCT01952444Written as ETI-204

Codes

What other systems call obiltoxaximab · ClinicalTrials.gg INT000536

MeSH (NLM) C000611266obiltoxaximabOne source NLM
UNII (FDA) 29Z5DNL48COBILTOXAXIMABConfirmed FDA, NLM, Wikidata
RxNorm 1746906One source FDA
Wikidata Q20707498obiltoxaximabConfirmed FDA, NLM, Wikidata
NCI Thesaurus C166561ObiltoxaximabOne source FDA
DrugBank DB05336One source Wikidata

System	Code	Name there	Checked by
MeSH (NLM)	C000611266	obiltoxaximab	One source NLM
UNII (FDA)	29Z5DNL48C	OBILTOXAXIMAB	Confirmed FDA, NLM, Wikidata
RxNorm	1746906	—	One source FDA
Wikidata	Q20707498	obiltoxaximab	Confirmed FDA, NLM, Wikidata
NCI Thesaurus	C166561	Obiltoxaximab	One source FDA
DrugBank	DB05336	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.